Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T12:50:58.663Z.
Calculation as of: 2026-10-06T12:50:58.663Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b6224f8b57f7cae82e1059df5c2bb45f5346f18e23f52b02bfc982dc52e16f10
PEG RATIO
N/A
Compugen Ltd.
Market Cap
$218.42M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Compugen Ltd. (CGEN) | $218.42M | N/A |
| Alector, Inc. (ALEC)vs › | $220.94M | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $202.05M | N/A |
| Biodesix, Inc. (BDSX)vs › | $236.56M | N/A |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | N/A |
| High Tide Inc. (HITI)vs › | $239.89M | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $245.65M | N/A |
PEG Ratio
N/A
P/E Ratio
6.2
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
